Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPalliative Oncology: Thalidomide
American Journal of Hospice and Palliative Medicine, 10/21/09
Prommer EE – After decades of disuse because of its teratogenic effects, thalidomide has had a resurgence of use as a promising therapeutic agent for multiple myeloma. Its mechanism of action involves activation of the immune system, antiangiogenic effects, and inhibition of cytokines. Thalidomide does not interact with the cytochrome oxidase system. It is not significantly metabolized, but it does undergo nonenzymatic hydrolysis in plasma. The resulting products are inactive. Despite the potential adverse effects of peripheral neuropathy, constipation, deep vein thrombosis, somnolence, rash, and orthostatic hypotension, thalidomide is an effective first–line agent for multiple myeloma in combination with dexamethasone or melphalan and prednisone. It has also been studied in the palliative care of patients with cytokine–based syndromes such as anorexia–cachexia syndrome. This review describes its use in oncology, hematology, and palliative care.
Related Articles
Impact of a pediatric palliative care program
Pediatric Blood & Cancer, 10/23/09
Relevance Score: 88%
A survey on physician knowledge and attitudes towards clinical use of morphine for cancer pain treatment in China
Supportive Care in Cancer, 11/16/09
Relevance Score: 87%
Management of Terminal Hemorrhage in Patients With Advanced Cancer: A Systematic Literature Review
Journal of Pain and Symptom Management, 10/16/09
Relevance Score: 87%
The Role of OROS Hydromorphone in the Management of Cancer Pain
Pain Practice, 10/27/09
Relevance Score: 86%
Medical Students' Views and Ideas About Palliative Care Communication Training
American Journal of Hospice and Palliative Medicine, 10/09/09
Relevance Score: 83%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma
British Journal of Haematology, 11/20/09
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
British Journal of Cancer, 11/20/09
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 11/20/09
Sponsor
Article Search
Sponsor